Zolbetuximab with chemo for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called zolbetuximab combined with chemotherapy (FOLFOX or CAPOX) for people with advanced or metastatic biliary tract cancer. It is for those whose tumors have a specific protein, Claudin 18.2, on at least 75% of cells. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic biliary tract cancer that cannot be removed by surgery.
- Your tumor has a high amount of a protein called Claudin 18.2 (at least 75% of cells, with moderate to strong staining). This is checked with a special lab test on a sample from a previous biopsy or surgery.
- You have had no more than one prior line of chemotherapy for advanced disease.
- You are in fairly good health (ECOG performance status 0 or 1, meaning you can do daily activities without much help).
- Your blood counts, kidney, and liver function are within specific limits (a doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
Hear when a new Advanced Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.